Background and Objectives. Cigarette smoking is common among cancer patients and is associated with negative outcomes. Electronic nicotine delivery systems (''e-cigarettes'') are rapidly growing in popularity and use, but there is limited information on their safety or effectiveness in helping individuals quit smoking.
B etween 2005 and 2009, cigarette smoking accounted for over 48% of all cancer-related deaths. 1 At least 75% of head and neck cancers are caused by tobacco and alcohol use, with tobacco associated with greater risk than alcohol. 2, 3 Evidence suggests that not only does smoking cause cancer, continued smoking after cancer diagnosis increases risk of developing other smoking-related illnesses (eg, coronary heart disease), second primary tumors, cancer recurrence, and mortality. [4] [5] [6] [7] [8] The majority of head and neck cancer patients attempt to quit smoking, but a substantial portion relapse back to smoking. 9, 10 Given patients' substantial smoking histories and difficulties quitting, it is perhaps unsurprising that our research team is increasingly receiving anecdotal reports of patients using electronic nicotine delivery systems (referred to here as ''e-cigarettes'' for purpose of simplicity and brevity).
E-cigarettes first became commercialized in China in 2003 and entered the US market in 2007. [11] [12] [13] E-cigarettes are electronic devices that heat a liquid to produce a vapor inhaled by the user (''vaper'') . Notably, vaporization does not involve combustion or tobacco smoke (see Figure 1) . A wide variety of brands and modifications exist. Many of these devices resemble cigarettes or cigars, but others appear more similar to pens, screwdrivers, or the tips from a hookah. The heating of the liquid inside an e-cigarette (''e-liquid'') is sometimes initiated by inhalation from the user but in other models is initiated by the pressing of a button. Most e-liquids contain nicotine from tobacco leaves in a mixture of glycerin or propylene glycol. Some e-liquids contain flavorings advertised as menthol, mint, cherry, coffee, chocolate, or as tasting similar to different varieties of tobacco. These e-liquids may be contained in disposable e-cigarettes themselves, replaceable cartridges, or refill liquids. On April 24, 2014, the Food and Drug Administration (FDA) released a proposed rule deeming e-cigarettes subject to FDA regulation, which, if enacted, will require e-cigarette manufacturers to report product and ingredient listings, only market new e-cigarettes after FDA review, only make reduced risk claims if FDA confirms there is scientific evidence, and include health warnings with e-cigarette packaging. This rule will be available for a 75-day public comment period before enactment. Providers and patients should be aware that ecigarettes are not approved as cessation devices and there is currently no federal oversight of e-cigarettes.
Although federal regulation of e-cigarettes has not yet been introduced in the United States, it is instructive to note regulations that have emerged elsewhere. In Canada, electronic nicotine delivery systems cannot be imported, marketed, or sold without being approved as a new drug. As a result, e-cigarettes that contain nicotine are currently illegal, but e-cigarettes without nicotine are legal as long as they do not include a health claim. 14 In the European Union, health ministers had attempted to move toward pharmaceutical regulations for e-cigarettes regardless of nicotine content. However, in October 2013, less stringent regulations were enacted: e-cigarettes should contain no more than 30 mg/ml of nicotine, should carry health warnings, and should not be sold to anyone under 18. Further, manufacturers and importers should supply authorities with a list of ingredients, and e-cigarettes are subject to the same advertising restrictions as tobacco products.
The lack of federal oversight in the United States has not deterred growth in the sale and use of electronic cigarettes. Surveys and other evidence indicate rapid, exponential growth, driven by increasingly aggressive marketing and declining price. Estimates of the US population who have ever used e-cigarettes in 2010 ranged from 2% to 3%. 15 A survey conducted in the beginning of 2012, before major televised e-cigarette advertisements, reported that about 8% had tried e-cigarettes with a 1% rate of current use; among current smokers, 32% had tried e-cigarettes and 6% used currently. 12 Most report smoking cessation as the primary reason for use. [16] [17] [18] Recently, traditional tobacco manufacturers entered the market, which is likely to accelerate e-cigarette usage. Given increased use among the general population and anecdotal reports of use by cancer patients, we recognized a need for providers to have a summary of the current, relevant literature on these products. To achieve this goal, we conducted a systematic review of the literature regarding the safety of e-cigarettes and their use as aides to quit tobacco cigarettes.
Methodology/Search Strategy
For this review, the literature was searched in PubMed (titles or abstracts) and Web of Science (titles or topics). The most recent search was conducted on November 20, 2013. Search terms used included electronic cigarette, electronic cigarettes, e-cig*, and electronic nicotine delivery. The initial search identified 277 original articles. Of these, 61 were not relevant, 75 were opinion/commentary articles, 29 were review articles, 29 provided empirical data regarding e-cigarette prevalence, and 28 provided empirical data not directly relevant, such as media exposure or effects of e-cigarettes on withdrawal symptoms or cognition. The remaining 55, that we review here, were articles with empirical data related to safety (n = 40) and tobacco cigarette cessation (n = 15) ( Figure 2 ). In addition, recent reviews assisted in structuring this review and providing background. [19] [20] [21] 
Discussion

Safety Data
Because e-cigarettes are developed by a variety of manufacturers and are unregulated, the contents of e-cigarettes vary widely and in some cases are not consistent with labeling. 22-24 Thus, it is not possible to make general statements regarding e-cigarette safety. Further, assessment of the health hazard associated with continued exposure to e-cigarettes over many years is not possible currently, as very few people have used e-cigarettes for an extended period of time. Moreover, the goal of safety assessments is controversial. Some argue that assessments should examine if e-cigarettes pose any risk to health, while others claim that the only relevant question is if they pose less risk than cigarette smoking. [25] [26] [27] [28] Despite these limits and controversies, there are some initial studies of e-cigarettes that provide useful information.
E-cigarettes are primarily used as a nicotine delivery system. Nicotine is known to be the major addictive chemical in tobacco and to have acute toxicity at high doses. 1 Although nicotine is linked to deregulation of essential biological processes, such as angiogenesis, which may promote the growth of preexisting tumors, 29 it is unclear if nicotine is carcinogenic in humans. Notably, a secondary analysis of the Lung Health Study found that use of Nicotine Replacement Therapies (NRT) was not associated with lung cancer. 30 On the other hand, long-term smokeless tobacco use increases the risk of oral cavity, esophageal, and pancreatic cancers, but not to the same degree as smoking and not at all for many other cancers associated with smoking. This potentially suggests that substances other than nicotine contribute to the cancer process. However, another explanation is that the reduced risk is partially or completely due to route of exposure. 1 Further, the carcinogen N-nitrosonornicotine (NNN) has been detected among some former smokers using NRT. 31, 32 Nonetheless, NNN is but 1 of over 250 chemicals known to be toxic or carcinogenic in tobacco smoke. 33 Thus, the 2014 Surgeon's General's Report notes the need for quantifying the level of risk from long-term use of NRT and other non-combusted sources of nicotine, especially if long-term use of these nicotine sources becomes more prevalent, as appears to be occurring with e-cigarettes. 1 Nicotine content varies by electronic cigarette manufacturer, and actual content is sometimes higher or lower than labeled. [21] [22] [23] 34, 35 Under clinical laboratory conditions, e-cigarette users are not always exposed to measurable levels of nicotine. 36, 37 Automatic smoking machines indicate that, similar to light and ultralight cigarettes, deeper inhalation is needed for e-cigarettes than conventional cigarettes, and the need for deep inhalation increases as vaping progresses. [38] [39] [40] Although the reduced exposure to nicotine may have some benefits, it is also a cause for concern, because lower nicotine products may result in compensatory behaviors. 41 Indeed, more experienced vapers using their own devices in the laboratory have been found to have elevated rates of plasma nicotine, topography indicates experienced vapers have longer puff duration than cigarette smokers vaping for the first time, saliva samples from vapers were found to have levels of nicotine metabolite that are more similar to cigarette smokers than users of nicotine replacement therapies, and survey data seem to indicate that vapers who are former smokers consume more nicotine from e-cigarettes than they previously did from tobacco cigarettes. [42] [43] [44] [45] These data suggest that vapers may compensate for any initial low levels of nicotine or that the absence of smoke irritants allows vapers to inhale more nicotine compared to smoking. This high usage may be of concern, especially if ecigarette vapor contains significant amounts of toxic chemicals besides nicotine.
To date, studies have found detectable levels of toxic chemicals in e-cigarettes, but generally at levels much lower than in tobacco smoke. For example, levels of toxicants have been reported to be 9 to 450 times lower than levels previously reported in tobacco smoke. 46 Nonetheless, these do include carcinogens previously found in tobacco smoke, such as formaldehyde, acetaldehyde, NNN, and 4(N-Nitrosomethyamino)-1-(3-pyridyl)-1-butanone (NNK). Most e-cigarettes contain propylene glycol, which at higher temperatures can oxidize and form formaldehyde, acetaldehyde, and methylglyoxal. 47 Some, but not all, of the ecigarette brands produced vapor with levels of formaldehyde and acetaldehyde significantly greater than contained in a medicinal nicotine inhaler. NNK and NNN were not found to be present in the nicotine inhaler, but were found in conventional cigarette smoke at concentrations 40 and 380 times greater than e-cigarette vapor, respectively. 46 Similarly, fine and ultrafine particulate matter emissions of an Italian brand of e-cigarette were 10 or 5 times lower than a conventional cigarette. 48 Other chemicals identified in ecigarettes include acrolein, volatile organic compounds (VOCs), and, in some rare cases, amino-tadalafil and rimonabant. 47,49-51 Finally, 1 study found concentrations of metals in e-cigarette aerosol that were higher than cigarette smoke, which the authors suggested demonstrated a need for improved quality control. 52 See Table 1 for a summary of studies of e-cigarette content.
Preclinical studies. An initial study found an association between e-liquid cytotoxicity and the number and concentration of flavoring chemicals used. 53 Subsequent studies found that 1 of 21 e-liquids produced vapor with cytotoxic effects. 54 A follow-up study found cytotoxicity in 4 of 20 samples and noted that higher voltage e-cigarettes resulted in reduced cell viability. 55 Cigarette smoke was significantly more cytotoxic, meeting cytotoxicity definition at 12.5% dilution, whereas none of the vapor solutions met that criteria even at 25% dilution. 55 In a 2014 conference presentation, researchers described a study of human bronchial epithelial cells carrying mutations in the TP53 and KRAS genes and reported that e-cigarette vapors enhanced the cells' cancerous behaviors, suggesting that e-cigarette exposure might contribute to lung cancer in individuals at high risk for the disease. 56 Further studies on the impact of electronic cigarette exposure on lung carcinogenicity are ongoing.
Acute effects. The use of e-cigarettes appears to have resulted in some positive health changes for former smokers.
Smokers (n = 13) converting to vaping demonstrated reduced carboxyhemoglobin levels after 2 weeks. 57 In a case report study, 1 smoker was able to relieve chronic idiopathic neutrophilia after switching from tobacco smoking to e-cigarettes. 58 E-cigarettes are also linked to negative effects. E-cigarettes, especially those with nicotine, reduce lung function. 59 However, this effect is less pronounced for e-cigarettes than for tobacco cigarettes. 44 Unlike tobacco cigarettes, e-cigarettes do not appear to significantly affect complete blood count. 60, 61 Studies reported that although both e-cigarettes and tobacco cigarettes increased pulse, increased inflammatory markers, and impacted measures of myocardial function, these changes were only significant for tobacco cigarettes. [62] [63] [64] See Table 2 for a summary of studies on acute effects. Various adverse events for e-cigarettes have been reported. The FDA reported that they received 47 reports about adverse events related to e-cigarette use: 8 were classified as serious, including pneumonia and chest pain; 39 were classified as minor, including headache and cough. 65 By examining reports by vapers in online forums, researchers classified negative effects from e-cigarettes as occurring primarily in the mouth, throat, and respiratory, neurological, sensory, and digestive systems. 66 Case studies have reported e-cigarette use resulting in lipid pneumonia and paroxysmal atrial fibrillation, both of which resolved after cessation of e-cigarette use. 67, 68 Poison center visits related to e-cigarette exposure were primarily from accidental ingestion resulting from leaky cartridges or other causes but also from dermal or ocular exposure as well as standard inhalation. [69] [70] [71] Three reported suicide attempts involving e-liquid ingestion were ultimately nonfatal, but 1 individual did commit suicide via e-liquid injection. 72, 73 Secondhand vaping. Toxic chemicals in e-cigarette vapor are not only inhaled by e-cigarette users; they are also released into the indoor environment. An early study reported no risk of harm to health via the inhalation route of environmental ecigarette vapor, 74 but later studies found that use of ecigarettes leads to emissions of aerosols, VOCs, flavoring substances, and nicotine, allowing for ''passive vaping. '' 48,75-77 Particle number concentrations of e-cigarette-generated aerosols were similar or even slightly higher than tobacco cigarettes; high nicotine content e-cigarettes appeared to produce greater particle number concentrations. 78 Presently, it is unclear if these particles represent a source of toxicity. Even if some level of toxicity is present, it seems unlikely to be as harmful as secondhand smoke, but the studies reviewed have yet to definitively answer this question. See Table 3 for a summary of passive exposure studies.
Efficacy Data on Smoking Cessation
Similar to safety data, there is considerable controversy about how to interpret cessation data. Beyond case studies and qualitative reports, 57,79-82 2 types of empirical evidence are reviewed here regarding the impact of e-cigarette usage on tobacco smoking: population-based studies and prospective trials. Population-based studies are generally surveybased observational studies that compare vapers to cigarette smokers. These are difficult to interpret for a variety of reasons. Most notably, individuals who purchase e-cigarettes differ significantly from those who do not. For example, vapers, in comparison to non-vaping cigarette smokers, are often younger and more affluent. 83,84 Another question concerns whether reduction (as opposed to cessation) of cigarette smoking should be considered as a positive outcome; cigarette smoking reduction is of questionable health benefit. 85 Further, self-report of cigarette smoking rate is notoriously unreliable when measured in cigarettes per day, as done in the majority of studies reviewed here. 86, 87 Even the few prospective trials have methodological limitations such as small sample size and no appropriate control group.
Survey studies. Surveys reveal that the majority of e-cigarette users are current or former smokers who believe e-cigarettes can help them quit smoking and are less harmful than tobacco cigarettes. [15] [16] [17] 20, 88 A 2010 survey e-mailed 4884 consecutive first-time purchasers of e-cigarettes in the US; of the 216 smokers who responded, about 31% were not smoking 6 months after their purchase. 89 A 2011 survey of current or recent former smokers (N = 1836) weighted to estimate US prevalence found that use of e-cigarettes was significantly associated with an unsuccessful quit attempt. 90 Similarly, another survey of current/former smokers in the US, the United Kingdom, Canada, and Australia found a significant reduction in cigarette smoking, but cessation rates did not differ significantly between e-cigarette users and non-users. 83 Another study examining tobacco quitline callers from 6 US states reported that about one-third of the sample reported ever using e-cigarettes; they were significantly less likely to have quit cigarettes at 7-month followup. 91 A study of former smokers in Europe (N = 111) who successfully substituted e-cigarettes for tobacco cigarettes Vapor contained particles comprised of tin, silver, iron, nickel, aluminum, and silicate and nanoparticles of tin, chromium, and nickel; 9 of 11 elements were equal or higher to cig smoke for at least 1 month reported that 42% quit in the first month; the majority (74%) used liquid with high nicotine concentration. 27 These survey studies are difficult to interpret because causality cannot be determined.
Clinical trials. We identified 5 prospective studies. The first 4 studies were conducted among current smokers uninterested in quitting. In the first study (N = 20), ecigarette experimentation was associated with reduced cigarette smoking after 1 week. 92 Similarly, in a second study involving smokers who were provided e-cigarettes for 24 weeks (N = 40), about 23% reported 30-day cigarette abstinence and about a third reduced cigarette consumption by at least 50%. 93 Results remained similar 18 months later, not including 17 who were lost to followup. 94 Notably, neither of the studies mentioned so far included control groups. A third study compared groups based on e-liquid nicotine content. One group (n = 100) received e-cigarettes with no nicotine, while a second group (n = 100) received 7.2 mg, and a third group (n = 100) received 7.2 mg for the first 6 weeks and then 5.4 mg for the remainder of the study. There were no significant differences between groups. Collapsing across groups, 11% and 9% of participants reported tobacco smoking abstinence at week 12 and week 52, respectively. 95 Similar results were found among schizophrenic smokers, with sustained abstinence in 2 of the 14 participants, with another 7 reporting a 50% reduction or more. 96 Finally, the most recent study randomly assigned 657 smokers interested in quitting to 3 groups: e-cigarettes with nicotine (n = 289), e-cigarettes without nicotine (n = 73), and nicotine transdermal patch (n = 295), a FDA-approved pharmacotherapy. 97, 98 Participants were given free supplies and instructed to use their e-cigarette or patch for 1 week before until 12 weeks after their quit day. The primary outcome, self-reported abstinence over the whole follow-up period (allowing 5 cigarettes total and verified by carbon monoxide), was assessed 6 months after the quit date. Rates of abstinence were not significantly different but was highest in the nicotine e-cigarettes group (n = 21, 7.3%), followed by the nicotine patch group (n = 17, 5.8%), and nicotine-free e-cigarettes group (n = 3, 4.1%). The authors attributed the lack of significant findings to lower rates of abstinence achievement observed during the study than assumed in statistical power calculations. Indeed, the rates appeared to be quite low in comparison to other studies. 99 See Table 4 for a summary of smoking cessation studies. Overall, these studies show that use of e-cigarettes appears to be associated with cessation or reduction of cigarette smoking for some individuals, but studies have yet to demonstrate that e-cigarettes are superior to an appropriate control condition.
Implications for Practice
Safety data indicate that e-cigarettes contain detectable levels of toxic substances, but generally at lower levels than tobacco cigarettes. Acute effects are generally similar to effects of tobacco cigarettes, but at a lower severity. Negative effects reported, for example, poisonings, appear to result primarily from accidental exposure. 69, 70, 100, 101 Secondhand vaping can occur, but current evidence is still ambiguous regarding related toxicity. Prospective trials appear to suggest ecigarettes can help some individuals quit or reduce smoking; however, evidence has yet to demonstrate rates higher than FDA-approved pharmacotherapies. Further, some individuals do not quit smoking, suggesting that e-cigarettes may allow them to maintain their tobacco dependence, perhaps by allowing nicotine use in locations where smoking is not permitted. In summary, available evidence suggest that ecigarettes warrant further investigation but cannot currently be unequivocally recommended as a smoking cessation strategy or harm reduction technique.
Health care providers, such as oncologists, can play a crucial role in promoting smoking cessation. 102 The most common model for delivering this information is summarized in Table 5 as the 5As approach: (1) ask the patient about their smoking, (2) advise them to quit if they are smoking, (3) assess their willingness and readiness to make a quit attempt, (4) assist them in their quit attempt by providing resources or referrals, and (5) arrange follow-up consultations to promote long-term cessation. This model is endorsed by the most recent treatment guidelines for tobacco dependence and is enhanced when providers advise (12-16 mg) 44% reduction in cigarettes per day following ad libitum use Step Description Action
Ask about cigarette use.
Determine whether a patient is currently using cigarettes at every appointment and document every response in the patient's medical record.
Directly ask the patient whether he or she is currently smoking tobacco cigarettes.
Advise patient to quit.
Encourage patients using tobacco cigarettes to quit smoking as soon as possible.
Tailor a clear and personalized message to the patient about the benefits of quitting and the risks associated with continued smoking. Assess b readiness to quit.
Determine whether a patient is ready to quit smoking and identify barriers to making a quit attempt.
Directly ask the patient whether he or she is ready to quit smoking. If so, proceed to Assist. If not, probe for source of lack of motivation. Assist b with quit attempt.
Provide assistance to patients who are motivated to quit.
Work with the patient on selecting a quit date. Explore potential triggers and cues that might promote relapse after quitting. Provide information about pharmacotherapy and referrals for psychotherapy. Arrange b follow-up contact.
Maintain contact with the patient to ensure that he or she is successfully maintaining abstinence. The Assess, Assist, and Arrange steps may be executed via a referral to a tobacco treatment specialist, including a tobacco cessation telephone quitline.
patients to use FDA-approved pharmacotherapies (eg, nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge, varenicline, bupropion) further improving cessation rates. [103] [104] [105] However, a large percentage of primary care physicians do not complete steps 3 through 5 in this model, and the same is true for cancer specialists, as less than 50% of practitioners discuss smoking cessation pharmacotherapies with their patients or provide assistance in helping them make a quit attempt. [106] [107] [108] These low percentages motivated the American Association for Cancer Research (AACR) to recommend universal assessment and documentation of tobacco use as well as improved provision of cessation assistance to all cancer patients who have used tobacco or recently quit. 109 Health and professional associations have begun to weigh in on e-cigarettes. AACR and the American Society of Clinical Oncology are currently preparing a joint policy statement. The American Cancer Society (ACS) had taken a very cautionary role, releasing a memo of support in 2010 of the effort to halt the sale of e-cigarettes in New York unless approved by the FDA. 110 However, more recent statements seem to be more open to potential public health benefits. A statement in 2011 by Dr Thomas Glynn, Director of Cancer Science and Trends at ACS, stressed the need for ''solid, independent data'' and stated that while e-cigarettes are not likely to be a ''magic bullet'' any more than any other quit smoking tool, they ''have the potential to make an important contribution to public health by helping some smokers stop.'' 111 A statement revised in July 2013 states that ACS ''has not taken a position on whether electronic cigarettes should be banned from the US market.'' 112 The American Lung Association reports that ''it is urgent for FDA to begin its regulatory oversight of e-cigarettes, which would include ingredient disclosure by e-cigarette manufacturers to FDA.'' 113 Finally, in an April 2014 publication, the Tobacco Control and Smoking Cessation Committee of the International Association for the Study of Lung Cancer (IASLC) released a statement on the use of e-cigarettes by cancer patients, stating that cancer patients who used ecigarettes to quit smoking should be congratulated but also monitored for adverse effects of e-cigarettes and encouraged to wean themselves off e-cigarettes, perhaps by switching to cessation pharmacotherapy. 114 Oncologists should remain vigilant regarding the evolving research and policy issues surrounding e-cigarettes and are directed to sources such as the FDA Center for Tobacco Products'''This Week in Tobacco'' to stay abreast of potential changes in evidence, recommendations, or guidelines. The FDA is expected to release regulatory statements regarding e-cigarettes in the near future. We recognize that the limited available scientific data on safety and efficacy, combined with the current lack of standardization and federal oversight, creates a difficult situation for health care providers. Most evidence suggests that e-cigarettes are less toxic than tobacco cigarettes, 47-51 but evidence regarding long-term effects of frequent use and the impact of ecigarette use on attempts to quit smoking is still lacking.
We advise clinicians to have frank discussions with patients about the known and unknown costs and benefits associated with e-cigarette use. Although use of FDA-approved pharmacotherapies certainly appears to be the more prudent choice at this juncture, we must recognize that many patients report turning to e-cigarettes following dissatisfying experiences with these pharmacotherapies. Unlike nicotine patches, e-cigarettes provide an acute dose of nicotine. Further, use of nicotine gum or lozenge may be difficult for some in this population due to postsurgical oral limitations. The nicotine inhaler is another FDA-approved pharmacotherapy that may prove helpful for some patients, but it provides a relatively low dose of nicotine, which is slowly absorbed through the buccal mucosa without reaching the lung in significant amounts. 115, 116 As mentioned earlier, nicotine toxicity is a concern, but given the numerous deleterious effects of continued smoking by head and neck cancer patients, smoking cessation remains the prepotent goal. Therefore, pending the emergence of compelling data, clinicians may consider keeping an open mind regarding patients' informed decisions to attempt smoking cessation in unconventional ways, including via the short-term use of e-cigarettes.
Vapers often report tobacco cessation as a primary motivation for use of e-cigarettes. As such, it is important that oncologists be aware of these devices. However, unlike the organizational support and guidelines recommending cessation of traditional tobacco products, limited guidelines exist for e-cigarette use in the oncology setting. Therefore, clinicians are advised to follow prior recommendations for primary care physicians to advise patients that the inhalation of the complex mixtures from e-cigarette vapors is not known to be safe, that there is not clear evidence that e-cigarettes help smokers to quit smoking, and that FDA-approved treatments for smoking cessation, proven safe and effective, are available. 19 Although research has improved our understanding of e-cigarettes since these initial 2011 recommendations, safety and efficacy remains uncertain. The exponential growth of e-cigarettes in recent years is now producing a similarly exponential growth in research into the area, but at this point there are still more questions than answers. Moving forward, it will be critical to understand if adolescents use e-cigarettes as a gateway to smoking, whether e-cigarette use promotes cessation or maintenance of smoking, and the long-term health consequences of direct or indirect exposure to e-cigarette vapor.
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